1. Home
  2. Analysis
  3. Simbrinza
  4. Pazeo

Simbrinza and Pazeo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Simbrinza (brimonidine tartrate; brinzolamide) and Pazeo (olopatadine hydrochloride). Common drug interactions include erythema among females and eye irritation among males.

The phase IV clinical study analyzes what interactions people have when they take Simbrinza and Pazeo. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Simbrinza?

Simbrinza has active ingredients of brimonidine tartrate; brinzolamide. It is often used in glaucoma. eHealthMe is studying from 4,543 Simbrinza users. Check the latest studies of Simbrinza.

What is Pazeo?

Pazeo has active ingredients of olopatadine hydrochloride. eHealthMe is studying from 1,256 Pazeo users. Check the latest studies of Pazeo.

On Jul, 14, 2026

11 people who take Simbrinza and Pazeo together, and have interactions are studied.

Simbrinza and Pazeo drug interactions.

What are the common drug interactions of Simbrinza and Pazeo, by gender? *:

female:

  1. Erythema (redness of the skin)
  2. Eye allergy
  3. Eye discharge
  4. Eye pruritus (eye itching)
  5. Eyelid disorder
  6. Hypersensitivity
  7. Ocular hyperaemia (an abnormally large amount of blood in eye)
  8. Conjunctivitis allergic (inflammation of the conjunctiva due to allergy)
  9. Drug ineffective
  10. Pneumonia

male:

  1. Eye irritation
  2. Eye pain
  3. Lacrimation increased
  4. Sleep disorder
  5. Vision blurred

What are the common drug interactions of Simbrinza and Pazeo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Conjunctivitis allergic (inflammation of the conjunctiva due to allergy)
  2. Drug hypersensitivity
  3. Loss of consciousness
  4. Ocular hyperaemia (an abnormally large amount of blood in eye)
  5. Pancreatic disorder
  6. Pancreatic enzymes increased
  7. Drug ineffective
  8. Erythema (redness of the skin)
  9. Eye allergy
  10. Eye discharge

What are the existing conditions these people have? *

  1. Conjunctivitis Allergic (inflammation of the conjunctiva due to allergy): 3 people, 27.27%
  2. High Blood Pressure: 1 person, 9.09%
  3. High Blood Cholesterol: 1 person, 9.09%
  4. Eye Irritation: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Simbrinza and Pazeo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Simbrinza and Pazeo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Simbrinza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pazeo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Simbrinza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pazeo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on brimonidine tartrate; brinzolamide and olopatadine hydrochloride (the active ingredients of Simbrinza and Pazeo, respectively), and Simbrinza and Pazeo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.